These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23506208)

  • 61. Pharmacology, toxicology and clinical safety of glycopyrrolate.
    Chabicovsky M; Winkler S; Soeberdt M; Kilic A; Masur C; Abels C
    Toxicol Appl Pharmacol; 2019 May; 370():154-169. PubMed ID: 30905688
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.
    Rossi A; Zanardi E; Poletti V; Cazzola M
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1383-92. PubMed ID: 26229457
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent.
    Dorinsky P; DePetrillo P; Siddiqui S; Maes A; Reisner C
    Pulm Pharmacol Ther; 2018 Aug; 51():18-25. PubMed ID: 29763659
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation.
    Borghardt JM; Weber B; Staab A; Kunz C; Kloft C
    Br J Clin Pharmacol; 2016 Sep; 82(3):739-53. PubMed ID: 27145733
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
    Ficker JH; Rabe KF; Welte T
    Pulm Pharmacol Ther; 2017 Aug; 45():19-33. PubMed ID: 28389258
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis.
    Pariser DM; Lain EL; Mamelok RD; Drew J; Mould DR
    Clin Pharmacokinet; 2021 May; 60(5):665-676. PubMed ID: 33433785
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials.
    D'Urzo A; Bader G; Shen S; Goyal P; Altman P
    NPJ Prim Care Respir Med; 2018 May; 28(1):18. PubMed ID: 29795478
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.
    Ismaila AS; Huisman EL; Punekar YS; Karabis A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2495-517. PubMed ID: 26604738
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Computed tomography (CT)-assessed bronchodilation induced by inhaled indacaterol and glycopyrronium/indacaterol in COPD.
    Shimizu K; Seto R; Makita H; Suzuki M; Konno S; Ito YM; Kanda R; Ogawa E; Nakano Y; Nishimura M
    Respir Med; 2016 Oct; 119():70-77. PubMed ID: 27692151
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden.
    Costa-Scharplatz M; Ställberg B; Goyal P; Asukai Y; Gruenberger JB; Price D
    Appl Health Econ Health Policy; 2015 Dec; 13(6):637-45. PubMed ID: 26324401
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi.
    Rogliani P; Calzetta L; Ora J; Lipsi R; Segreti A; Matera MG; Cazzola M
    Eur J Pharmacol; 2015 Aug; 761():383-90. PubMed ID: 25952728
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis.
    Muro S; Yoshisue H; Kostikas K; Olsson P; Gupta P; Wedzicha JA
    Respirology; 2020 Apr; 25(4):393-400. PubMed ID: 31339215
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients.
    Fogarty C; Hattersley H; Di Scala L; Drollmann A
    Respir Med; 2011 Mar; 105(3):337-42. PubMed ID: 21144724
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Nebulized glycopyrrolate (Lonhala Magnair) for COPD.
    Med Lett Drugs Ther; 2018 Apr; 60(1543):72. PubMed ID: 29667949
    [No Abstract]   [Full Text] [Related]  

  • 76. Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease.
    Radovanovic D; Mantero M; Sferrazza Papa GF; Valenti V; Aliberti S; Di Marco F; Santus P
    Expert Rev Respir Med; 2016 Oct; 10(10):1045-55. PubMed ID: 27552524
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study - the FAVOR study.
    Kardos P; Hagedorn-Peinz I
    Int J Chron Obstruct Pulmon Dis; 2018; 13():69-77. PubMed ID: 29317812
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study.
    Kerwin E; Hébert J; Gallagher N; Martin C; Overend T; Alagappan VK; Lu Y; Banerji D
    Eur Respir J; 2012 Nov; 40(5):1106-14. PubMed ID: 23060624
    [TBL] [Abstract][Full Text] [Related]  

  • 79. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
    Vogelmeier CF; Gaga M; Aalamian-Mattheis M; Greulich T; Marin JM; Castellani W; Ninane V; Lane S; Nunez X; Patalano F; Clemens A; Kostikas K;
    Respir Res; 2017 Jul; 18(1):140. PubMed ID: 28720132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.